Company: ARWR
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001628280-25-024666
Chunk: 26

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 26
---
ASH:BEGINNING OF PERIOD102,685 110,891 END OF PERIOD$185,709 $127,704 Supplementary disclosure of cash flows:Interest paid$(19)$— Income taxes paid$(81)$(3,014)Supplemental disclosure of non-cash investing activities:Capital expenditures included in accrued expenses$358 $7,265 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

4

Arrowhead Pharmaceuticals, Inc.

Notes to Consolidated Financial Statements 

(unaudited)

NOTE 1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

General and Recent DevelopmentsArrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the “Company”) are primarily engaged in developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (“RNAi”) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. The Company’s RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. The following table presents the Company’s current pipeline: Therapeutic AreaNameStageProduct RightsCardiometabolicplozasiranPhase 3ArrowheadzodasiranPhase 2bArrowheadolpasiranPhase 3AmgenARO-PNPLA3Phase 1ArrowheadGSK-4532990Phase 2bGSKARO-INHBEPhase 1/2aArrowheadARO-ALK7Phase 1ArrowheadPulmonaryARO-RAGEPhase 1/2aArrowheadSRP-1002 (ARO-MMP7)Phase 1/2aSareptaLiverfazirsiranPhase 3Takeda and ArrowheadGSK5637608Phase 2GSKNeuromuscularSRP-1001 (ARO-DUX4)Phase 1/2aSareptaSRP-1003 (ARO-DM1)Phase 1/2aSareptaCentral Nervous System (CNS)SRP-1004 (ARO-ATXN2)Phase 1/2aSareptaOtherARO